Natera, Inc. $NTRA Stock: Sumitomo Mitsui Trust Group Inc. Lowers Holdings

Sumitomo Mitsui Trust Group Inc. decreased its stake in shares of Natera, Inc. (NASDAQ:NTRA) by 17.4% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 531,443 shares of the medical research company’s stock after selling 112,200 shares during the quarter. Sumitomo Mitsui Trust Group Inc.’s holdings in Natera were worth $219,651,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Natera in the third quarter valued at approximately $7,545,000. Profund Advisors LLC boosted its position in Natera by 5.6% during the third quarter. Profund Advisors LLC now owns 6,553 shares of the medical research company’s stock worth $2,708,000 after purchasing an additional 348 shares during the period. Vise Technologies Inc. raised its position in shares of Natera by 5.3% in the third quarter. Vise Technologies Inc. now owns 2,010 shares of the medical research company’s stock valued at $831,000 after purchasing an additional 101 shares during the period. Americana Partners LLC acquired a new stake in shares of Natera during the 3rd quarter worth about $203,000. Finally, LJI Wealth Management LLC bought a new stake in shares of Natera during the 3rd quarter worth about $207,000. 99.90% of the stock is owned by institutional investors.

Analyst Ratings Changes

NTRA has been the subject of several research reports. Citigroup lifted their price target on Natera from $365.00 to $480.00 and gave the stock a “buy” rating in a report on Tuesday, October 6th. BTIG Research raised their price target on shares of Natera from $320.00 to $430.00 and gave the company a “buy” rating in a research note on Tuesday, October 27th. Morgan Stanley boosted their price target on Natera from $355.00 to $435.00 and gave the stock an “overweight” rating in a report on Monday, October 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Natera in a research report on Thursday, October 15th. Finally, Rothschild & Co Redburn initiated coverage on shares of Natera in a research report on Tuesday, September 8th. They set a “buy” rating and a $385.00 target price for the company. Two analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating, two have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $394.31.

Insider Activity

In other news, insider John Fesko sold 6,517 shares of the company’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $321.53, for a total value of $2,095,411.01. Following the completion of the transaction, the insider directly owned 197,257 shares of the company’s stock, valued at $63,424,043.21. This represents a 3.20% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Michael Brophy sold 1,906 shares of the stock in a transaction dated Friday, October 30th. The shares were sold at an average price of $425.55, for a total transaction of $811,098.30. Following the transaction, the chief financial officer owned 46,574 shares of the company’s stock, valued at approximately $19,819,565.70. The trade was a 3.93% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 44,556 shares of company stock valued at $16,084,051 over the last ninety days. Company insiders own 5.05% of the company’s stock.

Natera Price Performance

NASDAQ:NTRA opened at $414.30 on Monday. Natera, Inc. has a twelve month low of $181.00 and a twelve month high of $437.41. The company has a fifty day moving average of $377.06 and a 200-day moving average of $266.44. The firm has a market capitalization of $59.72 billion, a P/E ratio of -304.63 and a beta of 1.55.

Natera (NASDAQ:NTRA) last issued its earnings results on Thursday, August 6th. The medical research company reported ($0.47) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.02. Natera had a negative return on equity of 11.38% and a negative net margin of 7.11%. The company had revenue of $752.75 million for the quarter, compared to analyst estimates of $661.24 million. During the same period in the prior year, the firm earned ($0.74) earnings per share. Natera’s revenue for the quarter was up 37.7% on a year-over-year basis. On average, analysts anticipate that Natera, Inc. will post -1.14 EPS for the current fiscal year.

Key Headlines Impacting Natera

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Natera’s stock momentum remains strong after reaching a new 52-week high of approximately $436, reflecting continued investor enthusiasm for its oncology testing business and Signatera growth prospects. Natera reaches a fresh 52-week high
• Positive Sentiment: Recent ESMO oncology data, including 25 company presentations and additional Signatera evidence, could support broader clinical adoption and future revenue growth. Natera presents 25 ESMO abstracts
• Neutral Sentiment: Natera is scheduled to report third-quarter 2026 results after the market closes on November 5. The report will provide a near-term catalyst focused on Signatera testing volumes, pricing, reimbursement and profitability. Natera third-quarter results announcement
• Negative Sentiment: Several insiders sold shares this week, including the CEO, CFO and other executives. The transactions totaled roughly 11,500 shares, but each sale was made under a pre-arranged Rule 10b5-1 plan to cover tax withholding on vested equity awards, making the signal less concerning than discretionary selling. Natera insider selling
• Negative Sentiment: Zacks warned that Natera may report another quarterly loss and does not currently show the usual combination of positive estimate revisions and earnings momentum associated with a likely beat. With the stock trading well above its long-term moving averages and some valuation analyses estimating substantial downside to fair value, investors may be taking profits ahead of earnings. Natera earnings outlook

About Natera

Natera, Inc is a diagnostics company that develops and commercializes molecular testing services designed to provide personalized genetic and genomic information. Its tests are used across reproductive health, oncology and organ transplantation, with the company combining next-generation sequencing and bioinformatics to analyze DNA and monitor disease-related signals.

In reproductive health, Natera offers Panorama noninvasive prenatal screening, Horizon carrier screening and Vistara single-gene disorder screening.